Specific targeted agents like gefitinib, afatinib, osimertinib (for EGFR mutated tumors) and crizotinib/ceritinib (for ALK rearranged lung adenocarcinomas) have been approved by the Food and Drug Administration (FDA) for clinical use (3). Here, ALK is linked to lung adenocarcinoma.